^
Association details:
| Biomarker: | RET mutation |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor) + AST-487 (RET inhibitor, FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells
Excerpt:
Treatment of the RET mutant cell lines TT, TPC-1, and MZ-CRC-1 with... combined treatment with AST487 and INK128 at low concentrations suppressed growth and induced apoptosis.
DOI:
10.1530/ERC-13-0085
